Good afternoon, and thank you for joining us to discuss our second quarter results. With me on today's call is our President, Tim Turner; our CFO, Jeremiah Bickham; our CEO of Underwriting Managers, Miles Wuller; and Nick Mezick from Investor Relations. Ryan Specialty had a great quarter with strong momentum continuing across all of our strategic financial and operational objectives. We grew total revenue of 19.1% led by organic growth of 16.1%, building on the 22.3% organic growth in the second quarter of 2022. We also achieved double-digit growth in adjusted EBITDAC and adjusted net income on a year-over-year basis. We saw broad-based strength across our specialties, particularly in property and in many individual lines of business. The specific headwinds we noted on our prior calls were in line with our expectations and partially offset some of the very strong tailwinds we experienced in property. Overall, I'm very pleased with our performance in the quarter and throughout the first half of 2023. In addition to delivering great results, we continue to execute on our M&A strategy. In July, we completed 3 attractive and strategic acquisitions, which added scale and scope to our Wholesale specialty and lost our benefits practice. The first is Socius Insurance Services. Approximately $40 million of annual revenue Socius adds high-quality talent to our professional lines and cyber teams and deepens our scale and scope in key hubs like San Francisco, Tampa and Miami. We are confident in the outlook for this business, given our long-standing familiarity with the team and our proven ability to help firms grow on our platform through our relationships with the top 100 retail brokers access to our proprietary products and expand carrier relationships. We also completed 2 employee benefits acquisitions. Point6 Healthcare and ACE benefit partners, adding just under $10 million of annual revenue. These firms provide exceptional talent and foundational capabilities for Ryan Specialty Benefits. We have diligently assessed opportunities in the benefits market, targeting firms that have a track record of both growth and long-term margin greater than the industry average. And these medical stop-loss focus firms are perfectly aligned with those attributes. Medical stop-loss insurance plays the vital role by smoothing the volatility in health care spend through reinsuring a self-funded benefits plan against high-cost claims. We expect medical stop-loss insurance to continue to play a crucial role in financing and risk mitigation strategies, particularly as health care innovation accelerate in high-cost drugs and gene therapies become more prevalent. We are pleased to enter this niche that boasts over $25 billion in premium in the U.S. with a 12% compound annual growth rate since 2014. We believe there is a long runway for both organic and inorganic growth in benefits and are excited to have these capabilities to our specialties. Further on the M&A front, our pipeline remains robust. We remain disciplined in our pursuit of acquisitions, particularly in the current environment, as we will only move forward when all of our criteria are met. Each acquisition must be a strong cultural fit, strategic and accretive. We continue to make targeted investments during the quarter as we brought on additional talent to further enhance our current capabilities and develop areas where we anticipate our clients need us in the future. These investments, particularly in the recruitment of new colleagues offer the greatest returns for our shareholders and are part of a proven winning formula to maintain our long-term growth prospects. That takes us to ACCELERATE 2025, our 2-year restructuring program announced earlier this year. We are making investments that will enable continued growth, drive innovation, deliver sustainable productivity increases over the long term and accelerate margin improvement. We have made solid progress in the second quarter, which Jeremiah will discuss further. We remain on track to generate a targeted annual savings of at least $35 million in 2025 with cumulative special charges expected to be at least $65 million through the end of 2024. Throughout the second quarter, the E&S marketplace remained robust. E&S continues to provide solutions that are otherwise not available for hard-to-place risks. As we previously noted, we've invested significantly in those lines where we see clear opportunities to grow in addition to bolstering the lines of business our clients need us the most. We've also continued to expand our ability to serve brokers, agents and carriers through innovation and creating alternatives to traditional insurance placements in areas like cat property and transportation. Looking ahead, we expect favorable specialty insurance market dynamics to persist, and we remain confident that 2023 will continue to be another strong year for our firm. We are in a prime position to capture broader E&S tailwinds and also further capitalize on our specific lines of accelerated growth. Our differentiated business model allows us to remain ahead of the competition, and our flexibility enables us to quickly adapt and pivot when market conditions shift. We continue to expand our total addressable market through innovation and strategic acquisitions and further deepen our moat with scale, scope of intellectual capital. We're able to do all of this because of our exceptional team, who consistently deliver impressive results and value for our clients trading partners and ultimately, to our shareholders. Now I'm pleased to turn it over to Tim. Tim?